Showing 3061-3070 of 3415 results for "".
- FDA Approves Galderma's Restylane Defyne for Chin Augmentationhttps://practicaldermatology.com/news/fda-approves-galdermas-restylane-defyne-for-chin-augmentation/2460676/The U.S. Food and Drug Administration (FDA) has approved Restylane Defyne for the augmentation and correction of mild to moderate chin retrusion in adults over the age of 21. Restylane Defyne is a hyaluronic acid (HA) dermal filler that was first approved in 201
- Study: Aerolase Neo Elite Laser Is as Effective as the Gold Standard Laser for Treating Psoriasishttps://practicaldermatology.com/news/study-aerolase-neo-elite-laser-is-as-effective-as-the-gold-standard-laser-for-treating-psoriasis/2460674/The efficacy and tolerance of the 650-microsecond 1064-nm Nd:YAG laser (Aerolase NeoElite) is equivalent to the excimer laser for the treatment of mild to moderate psoriasis vulgaris of the arms and legs, according to a new study in the Journal of Drugs in Dermatology.
- Survey: Teledermatology Appointments Are Suitable Alternatives to Office Visitshttps://practicaldermatology.com/news/survey-teledermatology-appointments-are-suitable-alternatives-to-office-visits/2460669/The majority of dermatology patients find telehealth appointments to be a suitable alternative to in-person office visits, according to a survey in the Journal of Drugs in Dermatology.
- Study: Acute Itching in AD Linked to Environmental Triggershttps://practicaldermatology.com/news/study-acute-itching-in-ad-linked-to-environmental-triggers/2460658/Allergens in the environment often are to blame for episodes of acute itch in eczema patients, and that this itching often doesn’t respond to antihistamines because the itch signals are being carried to the brain along a previously unrecognized pathway that current drugs don’t ta
- Cerave Poll: Healthier Skin Tops New Year’s Resolutionshttps://practicaldermatology.com/news/cerave-poll-healthier-skin-tops-new-years-resolution-lists/2460652/The COVID-19 pandemic has taken its toll on every aspect of life including skin, according to a new survey from CeraVe. Fully 62 percent of Americans agree that they have experienced more skin troubles during the pandemic than ever before, with top concerns being dryness (51
- DermBiont Releases Positive Phase 2 Data for DBI-001 in Tinea pedis, Atopic dermatitishttps://practicaldermatology.com/news/dermbiont-releases-positive-phase-2-data-for-dbi-001-in-tinea-pedis-atopic-dermatitis/2460649/Data from two, separate phase 2 clinical trials of investigational DBI-001 for the treatment of tinea pedis and atopic dermatitis show benefit, according to drug developer DermBiont. In the phase 2b clinical study of DBI-001 in tinea p
- For Upper Facial Lines, DaxibotulinumtoxinA Succeeds in Phase 2https://practicaldermatology.com/news/for-upper-facial-lines-daxibotulinumtoxina-succeeds-in-phase-2/2460637/Topline efficacy and safety results from the phase 2 multicenter, open-label study of Revance's investigational drug candidate DaxibotulinumtoxinA for Injection for the combined treatment of upper facial lines, show high levels of patient satisfaction. The 36-week study enrolled 48
- Evelo's AD Candidate Meets Phase 1b Endpointshttps://practicaldermatology.com/news/evelos-ad-candidate-meets-phase-1b-endpoints/2460631/Evelo Biosciences, Inc.’s investigational atopic dermatitis treatment EDP1815 was well tolerated with no serious adverse events in a phase 1b clinical trial. According to the company, the oral drug candidate studied in 23 evaluable subjects with
- FDA Defers Approval of Revance's Toxin Due to COVID-19 Related Travel Restrictions Impacting Manufacturing Site Inspectionhttps://practicaldermatology.com/news/fda-defers-approval-of-revances-toxin-due-to-covid-19-related-travel-restrictions-impacting-manufacturing-site-inspection/2460628/The U.S. Food and Drug Administration (FDA) deferred a decision on the Biologics License Application (BLA) for Revance’s DaxibotulinumtoxinA for Injection, an investigational neuromodulator product for the treatment of moderate to severe glabellar lines. In a communication r
- Research Identifies Long-Term Benefits of Incorporating Ceramides into Baby Skincarehttps://practicaldermatology.com/news/research-identifies-long-term-benefits-of-incorporating-ceramides-into-baby-skincare/2460612/Using ceramide-infused products on baby skin may have long-term benefits lasting into adulthood, according to a newly published study in the Journal of Drugs in Dermatology. Beyond n